Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

BioPlus Specialty Pharmacy Now Dispensing Newly Approved AML Cancer Medication Daurismo™

BioPlus Specialty Pharmacy
Posted on: 04 Dec 18
BioPlus Specialty Pharmacy Now Dispensing Newly Approved AML Cancer Medication Daurismo™ BioPlus Specialty Pharmacy, one of the nation's leading innovative specialty pharmacies, can now dispense the latest FDA-approved limited distribution medication Daurismo (glasdegib) for acute myeloid leukemia (AML).

PR Newswire

ALTAMONTE SPRINGS, Fla., Dec. 4, 2018

ALTAMONTE SPRINGS, Fla., Dec. 4, 2018 /PRNewswire-PRWeb/ -- BioPlus Specialty Pharmacy (BioPlus), a leading innovative specialty pharmacy, is now dispensing the limited distribution oral cancer medication Daurismo™ (glasdegib) from Pfizer Inc. The U.S. Food and Drug Administration approved Daurismo on November 21, 2018. With the addition of Daurismo, BioPlus now has access to 62 limited distribution drugs, with 70% of these in the category of cancer medications.

Daurismo is an oral medication approved for the treatment of acute myeloid leukemia (AML). It will be used in combination with the chemotherapy medication cytarabine for adults age 75+ who have newly-diagnosed AML along with additional chronic health conditions that prevent the use of intensive chemotherapy. Daurismo is available to a limited distribution network of specialty pharmacies, which includes BioPlus.

Daurismo marks the fourth FDA approval for Pfizer medications in just the past two months; all of which have been limited distribution drugs. In addition, Daurismo received an Orphan Drug designation from the FDA, which is associated with incentives to assist the development of drugs for rare diseases.

"Daurismo's approval as a first-line treatment for AML offers a new treatment option for patients who cannot tolerate intensive chemotherapy," shares Sharon Ferrer, VP of Pharmaceutical Relations at BioPlus. "BioPlus is now dispensing this important new option for patients with AML. We are able to assist patients with prompt treatment starts because of our 2-Day Ready 2 Ship program that quickly gets medications to patients," she adds.

AML is a type of cancer that forms in the bone marrow and rapidly progresses. This year, according to the National Cancer Institute, 19,520 patients will be diagnosed with this form of leukemia. Of these, an estimated half of patients are not able to be treated with intensive chemotherapy due to comorbidities and chemotherapy-related toxicities.

About BioPlus Specialty Pharmacy
BioPlus Specialty Pharmacy is a leading independent, national specialty pharmacy and the first and only specialty pharmacy to offer a two-hour turnaround from referral to patient acceptance. Our company celebrates 29 years of innovative excellence in specialty pharmacy, working closely with payers and the pharmaceutical industry, as well as with prescribers to get prompt treatment for patients, and directly supporting our patients nationwide to achieve optimal health outcomes. We provide a complete range of specialty services, including for cancer, multiple sclerosis, hepatitis C, and other complex, chronic conditions. BioPlus, a privately-held, pharmacist-owned company based in Altamonte Springs, Florida, is accredited by URAC, VIPPS, and ACHC with a Distinction in Oncology.

For information: http://www.bioplusrx.com or
Contact: info(at)bioplusrx(dot)com
Phone: 1-888-292-0744

 

SOURCE BioPlus Specialty Pharmacy

PR Newswire
www.prnewswire.com

Last updated on: 04/12/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.